Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aspire Biopharma Holdings ( (ASBP) ) has provided an update.
On February 4, 2025, Aspire Biopharma Holdings’ stockholders approved a 2024 Stock Incentive Plan, and on January 8, 2026, the board confirmed a share limit of 4,890,000 under the plan, enabling the company to grant a range of equity awards to eligible employees, directors and consultants to better align their interests with long-term shareholder value. Also on January 8, 2026, the board adopted standard forms of restricted stock unit and stock option award agreements for use under the plan, formalizing the mechanisms through which executives, directors and other employees can receive and vest in equity-based compensation, signaling a structured approach to talent retention and incentive alignment.
More about Aspire Biopharma Holdings
Aspire Biopharma Holdings, Inc. is a biopharmaceutical company, with operations centered on developing healthcare and drug-related products and services, and it relies on equity-based compensation to attract and retain employees, directors and consultants critical to its growth strategy.
Average Trading Volume: 41,615,138
Technical Sentiment Signal: Sell
Current Market Cap: $8.13M
See more insights into ASBP stock on TipRanks’ Stock Analysis page.